Enzyme engineering opens door to novel therapies for Parkinson’s, cancers and other hard-to-target protein diseases (IMAGE)

Scripps Research Institute

Enzyme engineering opens door to novel therapies for Parkinson’s, cancers and other hard-to-target protein diseases

Caption

α-Synuclein modulates neurite outgrowth as seen here in human cells, potentially suggesting involvement of the protein in learning processes of the brain. However, dysregulated α-Synuclein leads to neurotoxic aggregates associated with incurable Parkinson’s disease.

Credit

Scripps Research

Usage Restrictions

Can be used with related coverage and with credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.